Brought to you by 
Alba Therapeutics licenses IP from U. of Maryland, Baltimore
18 Dec 2015
Executive Summary
Alba Therapeutics (hopes to develop drugs and drug delivery adjuvants) has acquired exclusive rights from the University of Maryland, Baltimore to about 100 patents pertaining to the use of the zonulin endogenous signaling pathway for all applications, excluding clinical diagnostics.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alba Therapeutics licenses IP from U. of Maryland, Baltimore
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice